| pubmed-article:12655443 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0205267 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C0439228 | lld:lifeskim |
| pubmed-article:12655443 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:12655443 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12655443 | pubmed:dateCreated | 2003-3-25 | lld:pubmed |
| pubmed-article:12655443 | pubmed:abstractText | To improve the therapeutic efficacy and minimize the toxicity of 5-fluorouracil (5-FU), intermittent therapy consisting of alternate 24-h intravenous infusion and based on differences in generation time (T(G)) between normal cells and tumor cells was investigated. | lld:pubmed |
| pubmed-article:12655443 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12655443 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12655443 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12655443 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12655443 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:12655443 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:KawamuraHiden... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:SaitoKazuyosh... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:GotohMitsukaz... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:TerashimaMasa... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:AbeKaoruK | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:TakaganeAkino... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:FujiwaraHisat... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:IrinodaTakash... | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:OyamaKenichiK | lld:pubmed |
| pubmed-article:12655443 | pubmed:author | pubmed-author:ShirasakaTets... | lld:pubmed |
| pubmed-article:12655443 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12655443 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:12655443 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12655443 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12655443 | pubmed:pagination | 240-6 | lld:pubmed |
| pubmed-article:12655443 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:meshHeading | pubmed-meshheading:12655443... | lld:pubmed |
| pubmed-article:12655443 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12655443 | pubmed:articleTitle | Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. | lld:pubmed |
| pubmed-article:12655443 | pubmed:affiliation | Department of Surgery 1, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima, Japan. mterashi@fmu.ac.jp | lld:pubmed |
| pubmed-article:12655443 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12655443 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12655443 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
